The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.
A reply to the Governor of Texas comment.
Proud to sign a Statement of Mutual Cooperation with Secretary Kemi Badenoch today in London to deepen the strong economic relationship between Texas and the U.K.
Reply
“Awesome news! We are currently opening a new company in San Antonio with exciting technology coming out of the UK, would love to explain how this partnership will save many lives!”
Foreign Application Priority Data - not sure if this means it’s a priority application for grant. (If it is 12months nearly up)
Exciting to read
Treating
[0172] In one aspect the present invention relates to a method for treating a subject with cancer comprising administering to the subject a cancer therapeutic; wherein the subject has been identified as having cancer by a method of the present invention.
[0173] In another aspect the present invention provides an anticancer drug for use in treating cancer wherein the subject has been identified as having cancer by a method of the present invention. In a further aspect, the present invention relates to an anticancer lung cancer drug for use in treating lung cancer wherein the subject has been identified as having lung cancer by a method of the present invention.
Anticancer Drug
[0175]
An ‘anticancer drug’ is synonymous with a cancer therapeutic and refers to an entity which may be used to treat cancer.
0176]
The anti-cancer drug may be a cytokine or haematopoietic factor including, but not limited to, IL-1, IL-2, IL-4, IL-5, IL-13, IL-6, CSF-1, M-CSF, GM-CSF, IFNα, IFNβ, IFNγ, IL-10, IL-12, VEGF, bone morphogenic proteins, FGFs, TNF and TGFβ.
0178]
The anticancer drug may be a siRNA or shRNA.
[0179]
Suitably, the anticancer drug may be an anticancer lung cancer drug. An anticancer lung cancer drug refers to an entity which may be used to treat lung cancer.
According to company forecast they need not less than £1M additional funding. (£0.5M to fund the corporate and operational overheads of the business and £0.5M for the future additional development of projects.)
Drawdown in full covers half.
Also no update re outsourcing future manufacturing process to a partner specialising in manufacture?
There are a lot of questions and currently nothing from the CEO.
Other than options does the CEO hold any shares ?
If it’s at his home then I would suggest it’s set up for tax purposes. Nothing more exciting
https://www.irs.gov/newsroom/how-small-business-owners-can-deduct-their-home-office-from-their-taxes
7 months on. Will they RNS the commencement production and clinical trials or is it going to be results of clinical trial and move to commercial production?
After patent grant or not?
“The next steps are to finalise standard production and operating protocols and to commence clinical trials that should lead to an accredited Laboratory Developed (LDT) test for launch initially in the USA. “
This the one ?
Cizzle Bio Inc.
Company Number
0805434362
Company Type
Domestic For-Profit Corporation
Jurisdiction
Texas (US)
Registered Address
1 CHARTERWOOD
SAN ANTONIO
78248-1660
TX
USA
Alternative Names
Cizzle Bio Inc. (trading name, 2024-02-25 - )
Agent Name
William Behnke
Agent Address
1 Charterwood, San Antonio, TX, 78248, USA
Approaching key date anniversary of submission. Average US pendency is around 25 months. Be interesting to see if there is an update regarding the patent application around or after the application anniversary.
Will CIZ wait until the grant of the patent for their CIZ1b lung cancer test process application to an existing testing platform.